Small Molecules
26 February 2018
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF25 February 2018
KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain25 February 2018
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer22 February 2018
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis22 February 2018
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP4200622 February 2018
Treatment with Novartis’ Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation21 February 2018
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids21 February 2018
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial20 February 2018
Kancera AB (publ) Reports Positive Results from a Phase I Study in Healthy Subjects With its Lead Immunoregulating Drug Candidate KAND56718 February 2018
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18 February 2018
PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER218 February 2018
AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn’s Disease at 52 Weeks18 February 2018
AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting16 February 2018
OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis15 February 2018
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation14 February 2018
Galmed Announces ARRIVE Study DataNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports